Misplaced Pages

Ilunocitinib

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is an old revision of this page, as edited by Boghog (talk | contribs) at 06:32, 21 December 2024 (added missing identifiers to drug box). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 06:32, 21 December 2024 by Boghog (talk | contribs) (added missing identifiers to drug box)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Veterinary medication

Pharmaceutical compound
Ilunocitinib
Clinical data
Trade namesZenrelia
Other namesLY-3411067
License data
Routes of
administration		By mouth
ATC code
  • None
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC17H17N7O2S
Molar mass383.43 g·mol
3D model (JSmol)
SMILES
  • C1CC1S(=O)(=O)N2CC(C2)(CC#N)N3C=C(C=N3)C4=C5C=CNC5=NC=N4
InChI
  • InChI=InChI=1S/C17H17N7O2S/c18-5-4-17(9-23(10-17)27(25,26)13-1-2-13)24-8-12(7-22-24)15-14-3-6-19-16(14)21-11-20-15/h3,6-8,11,13H,1-2,4,9-10H2,(H,19,20,21)
  • Key:RVOUEXFKIYNODQ-UHFFFAOYSA-N

Ilunocitinib, sold under the brand name Zenrelia, is a veterinary medication used for the treatment of pruritus (itching) in dogs.

Ilunocitinib was approved for medical use in the United States in September 2024, and in Canada in December 2024.

Medical uses

Ilunocitinib is indicated for the control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least twelve months of age.

Contraindications

It is not safe to administer vaccines to dogs that are concurrently receiving ilunocitinib.

Society and culture

Legal status

Ilunocitinib was approved for medical use in the United States in September 2024, and in Canada in December 2024.

Names

Ilunocitinib is the international nonproprietary name.

Ilunocitinib is sold under the brand name Zenrelia.

References

  1. ^ "Notice: Multiple additions to the Prescription Drug List (PDL) [2024-12-20]". Health Canada. 20 December 2024. Retrieved 21 December 2024. Text was copied from this source. Reproduction is authorized provided the source is acknowledged.
  2. "Zenrelia". U.S. Food and Drug Administration (FDA). Retrieved 21 December 2024.
  3. ^ https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/15865
  4. "FDA Approves New Treatment for Allergic Skin Conditions in Dogs". U.S. Food and Drug Administration (FDA). 19 September 2024. Retrieved 21 December 2024. Public Domain This article incorporates text from this source, which is in the public domain.
  5. ^ "Dear Veterinarian Letter regarding important safety information associated with the use of Zenrelia (ilunocitinib tablets) for controlling pruritus associated with allergic dermatitis and atopic dermatitis in dogs". U.S. Food and Drug Administration (FDA). 1 October 2024. Retrieved 21 December 2024. Public Domain This article incorporates text from this source, which is in the public domain.
  6. "Recent Animal Drug Approvals". U.S. Food and Drug Administration. 1 October 2024. Retrieved 21 December 2024.
  7. World Health Organization (2022). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 87". WHO Drug Information. 36 (1). hdl:10665/352794.
Immunosuppressive drugs / Immunosuppressants (L04)
Intracellular
(initiation)
Antimetabolites
Macrolides/
other IL-2 inhibitors
IMiDs
Intracellular
(reception)
IL-1 receptor antagonists
mTOR
Extracellular
Antibodies
Monoclonal
Serum target
(noncellular)
Cellular
target
Unsorted
Polyclonal
-cept (Fusion)
Unsorted
Portal:


Stub icon

This veterinary medicine–related article is a stub. You can help Misplaced Pages by expanding it.

Categories: